ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG CỦA BỆNH NHÂN KÍCH THÍCH BUỒNG TRỨNG BẰNG PHÁC ĐỒ ANTAGONIST VỚI DELTA-FOLLITROPIN (REKOVELLE)

Abstract

Objective:To evaluate the clinical and paraclinical characteristics of patients undergoing ovarian stimulation using the Antagonist protocol with Delta-follitropin (Rekovelle). Subjects and Methods:The study was conducted on 71 infertile couples treated at the Military Institute of Clinical Embryology from August 2023 to December 2024. The inclusion criteria were patients undergoing in vitro fertilization (IVF) with ovarian stimulation using Rekovelle, who agreed to participate in the study. Exclusion criteria included patients with endocrine disorders such as pituitary adenoma, hypothalamic tumors, thyroid dysfunction, breast tumors, ovarian tumors, uterine fibroids, genital malformations, as well as cases involving egg donation or egg preservation. The study employed a combination of retrospective and prospective methods with a cross-sectional descriptive design. Results:The average age of the patients was 36.31 ± 4.58 years. The rate of secondary infertility was 78.9%, while primary infertility accounted for 21.1%. The duration of infertility ranged from 1 to 14 years, with 70.4% of patients experiencing infertility for less than 5 years. The number of IVF cycles ranged from 1 to 4, with 1–2 cycles accounting for 81.7%. The average BMI of the patients was 21.78, and the AMH level was 1.33 (0.81–2.34) ng/mL. AMH levels varied by age group. FSH levels ranged from 3.01 to 17.1, while LH levels ranged from 2.46 to 11.48. The proportion of patients with an antral follicle count (AFC) of more than 5 follicles was 84.5%, while those with fewer than 5 follicles accounted for 15.5%. On day 2 of the menstrual cycle, the endometrial thickness was less than 8 mm in the majority of patients (80.3%), 8–12 mm in 18.3%, and more than 12 mm in 1.4%.  Conclusion: The study evaluated the clinical and paraclinical characteristics of patients using the Antagonist protocol with Delta-follitropin (Rekovelle). These findings provide a basis for further research and evaluation in studies involving infertile patients using this protocol.